Lancet Hiv最新文献

筛选
英文 中文
Epidemiology and management of HIV-2. HIV-2的流行病学和管理。
IF 14.6 1区 医学
Lancet Hiv Pub Date : 2026-10-01 Epub Date: 2026-08-26 DOI: 10.1016/S2352-3018(26)00170-0
Serge Paul Eholié, Charlotte Charpentier, Zelica Diallo, Oumarou I Wone Adama, David da Silva Té, Diane Descamps, Didier Koumavi Ekouevi
{"title":"Epidemiology and management of HIV-2.","authors":"Serge Paul Eholié, Charlotte Charpentier, Zelica Diallo, Oumarou I Wone Adama, David da Silva Té, Diane Descamps, Didier Koumavi Ekouevi","doi":"10.1016/S2352-3018(26)00170-0","DOIUrl":"10.1016/S2352-3018(26)00170-0","url":null,"abstract":"<p><p>HIV-2 remains a neglected component of the global HIV epidemic, predominantly affecting west Africa but also present in Europe and other regions through historical and migratory links. Although generally characterised by lower transmissibility and slower disease progression than HIV-1, HIV-2 poses distinct diagnostic, therapeutic, and programmatic challenges. Research, implementation, and advocacy efforts aimed at reducing HIV-2 infection must account for the limitations of available typing tools, the restricted access to validated viral load assays, the virus' intrinsic resistance to certain antiretroviral drug classes, and the gaps in retention in care that hinder progress towards global treatment targets. Strengthening collaborative research, improving diagnostic capacity, and integrating HIV-2 into broader HIV policy frameworks are essential to optimise patient outcomes and to advance the global HIV response.</p>","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e735-e744"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148833371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Charting the USA's spiralling HIV response 美国对艾滋病毒的反应呈螺旋式上升
IF 16.1 1区 医学
Lancet Hiv Pub Date : 2026-10-01 DOI: 10.1016/s2352-3018(26)00260-2
Andrew Green
{"title":"Charting the USA's spiralling HIV response","authors":"Andrew Green","doi":"10.1016/s2352-3018(26)00260-2","DOIUrl":"https://doi.org/10.1016/s2352-3018(26)00260-2","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"3 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149150379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Virological failure and treatment interruption among people with unsuppressed viral load on antiretroviral therapy: a cross-sectional analysis of Population-based HIV Impact Assessment surveys in seven sub-Saharan African countries 在接受抗逆转录病毒治疗的病毒载量未受抑制的人群中,病毒学失败和治疗中断:对撒哈拉以南非洲7个国家基于人群的艾滋病毒影响评估调查的横断面分析
IF 16.1 1区 医学
Lancet Hiv Pub Date : 2026-10-01 DOI: 10.1016/s2352-3018(26)00171-2
Mansoor Farahani,Suzue Saito,Shannon M Farley,Theodore F Smart,Felix Ndagije,Eduardo Samo Gudo,Wilford L Kirungi,Rose Kolola Nyirenda,Owen Mugurungi,Wolfgang Hladik,Hetal K Patel,Samuel Sendagala,Talent Maphosa,Munyaradzi Pasipamire,Alexander Kailembo,Fred Asiimwe,Andrew C Voetsch,Wafaa M El-Sadr
{"title":"Virological failure and treatment interruption among people with unsuppressed viral load on antiretroviral therapy: a cross-sectional analysis of Population-based HIV Impact Assessment surveys in seven sub-Saharan African countries","authors":"Mansoor Farahani,Suzue Saito,Shannon M Farley,Theodore F Smart,Felix Ndagije,Eduardo Samo Gudo,Wilford L Kirungi,Rose Kolola Nyirenda,Owen Mugurungi,Wolfgang Hladik,Hetal K Patel,Samuel Sendagala,Talent Maphosa,Munyaradzi Pasipamire,Alexander Kailembo,Fred Asiimwe,Andrew C Voetsch,Wafaa M El-Sadr","doi":"10.1016/s2352-3018(26)00171-2","DOIUrl":"https://doi.org/10.1016/s2352-3018(26)00171-2","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"13 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149089537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reimagining HIV service integration 重新构想艾滋病毒服务整合
IF 16.1 1区 医学
Lancet Hiv Pub Date : 2026-10-01 DOI: 10.1016/s2352-3018(26)00254-7
Gifty Marley,Nittaya Phanuphak,Weiming Tang
{"title":"Reimagining HIV service integration","authors":"Gifty Marley,Nittaya Phanuphak,Weiming Tang","doi":"10.1016/s2352-3018(26)00254-7","DOIUrl":"https://doi.org/10.1016/s2352-3018(26)00254-7","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"22 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149089541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Plasma dolutegravir exposure testing to identify people with HIV at highest risk for dolutegravir resistance (ITREMA-2): a two-centre, prospective implementation study in South Africa. 血浆多替替韦暴露试验以确定多替替韦耐药风险最高的艾滋病毒感染者(ITREMA-2):一项在南非开展的双中心前瞻性实施研究。
IF 14.6 1区 医学
Lancet Hiv Pub Date : 2026-10-01 Epub Date: 2026-09-02 DOI: 10.1016/S2352-3018(26)00144-X
Kim Steegen, Jeremy Nel, Erin H Smeijsters, Chijioke N Umunnakwe, Karabo Mophiring, Sean Currin, Wouter M Tiel Groenestege, Matthijs van Luin, Lucas E Hermans, Hugo A Tempelman, Lucia Hans, Lise Jamieson, Siphamandla Gumede, Athini Nyatela, Willem D F Venter, Monique Nijhuis, Annemarie M J Wensing
{"title":"Plasma dolutegravir exposure testing to identify people with HIV at highest risk for dolutegravir resistance (ITREMA-2): a two-centre, prospective implementation study in South Africa.","authors":"Kim Steegen, Jeremy Nel, Erin H Smeijsters, Chijioke N Umunnakwe, Karabo Mophiring, Sean Currin, Wouter M Tiel Groenestege, Matthijs van Luin, Lucas E Hermans, Hugo A Tempelman, Lucia Hans, Lise Jamieson, Siphamandla Gumede, Athini Nyatela, Willem D F Venter, Monique Nijhuis, Annemarie M J Wensing","doi":"10.1016/S2352-3018(26)00144-X","DOIUrl":"10.1016/S2352-3018(26)00144-X","url":null,"abstract":"<p><strong>Background: </strong>Dolutegravir resistance is increasingly reported in treatment-experienced people with HIV in low-income and middle-income countries. Resistance testing resources are sparse, and viral rebound often reflects adherence lapses rather than resistance. Efficient strategies are needed to target testing to individuals at highest risk. We evaluated a reflex laboratory approach using plasma dolutegravir exposure to guide resistance testing in routine care.</p><p><strong>Methods: </strong>In this prospective implementation study at two public-sector clinics in Johannesburg, South Africa, we analysed adults (aged ≥18 years) on dolutegravir-based antiretroviral therapy (ART) with viral rebound of 400 copies per mL or higher. From May 18, 2023, to Jan 10, 2025, we tested residual routine viral load samples for dolutegravir exposure using an enzyme immunoassay. If dolutegravir was detectable (≥20 ng/mL), we did reflex resistance testing on the same specimen; retrospective sequencing was done at study end for dolutegravir-undetectable samples. We modelled costs comparing the reflex approach with standard of care.</p><p><strong>Findings: </strong>We analysed 400 samples from 288 individuals; 160 (56%) were female and 128 (44%) male, the median age was 44 years (IQR 35-50), and 240 (83%) had previous non-dolutegravir ART exposure. Plasma dolutegravir was detectable in 108 (38%) participants. Among those with successful sequencing, dolutegravir resistance occurred in 13 (13%) of 102 participants with detectable dolutegravir and three (2%) of 138 with undetectable dolutegravir, yielding an overall prevalence of 6·7% dolutegravir resistance and a negative predictive value for absence of dolutegravir resistance of 97·8% (95% CI 93·5-99·5). Dolutegravir resistance was associated with detectable dolutegravir (odds ratio [OR] 3 [95% CI 1-9], p=0·031), nucleoside reverse transcriptase inhibitor mutations (OR 33 [4-264], p=0·0009), non-nucleoside reverse transcriptase inhibitor mutations (OR 17 [2-135], p=0·0068), or M184V (OR 20 [4-92], p=0·0002). Cost modelling showed a 23% reduction in monitoring cost per person using the reflex strategy after confirmed viraemia versus current national guidelines.</p><p><strong>Interpretation: </strong>Laboratory-initiated reflex plasma dolutegravir exposure testing provides an objective, cost-efficient strategy to predict the absence of dolutegravir resistance and supports adherence management, enabling timely, individualised treatment decisions. Reflex dolutegravir exposure testing could enhance clinical decision making, improve treatment outcomes, and strengthen HIV treatment and resistance monitoring algorithms in programmatic settings.</p><p><strong>Funding: </strong>The Amsterdam Dinner Foundation and Aidsfonds, the Netherlands Organisation for Scientific Research, ZonMw, and WOTRO.</p>","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e713-e722"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148882372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
100% committed to life. 100%忠于生活。
IF 14.6 1区 医学
Lancet Hiv Pub Date : 2026-10-01 Epub Date: 2026-07-22 DOI: 10.1016/S2352-3018(26)00196-7
Ed Holt
{"title":"100% committed to life.","authors":"Ed Holt","doi":"10.1016/S2352-3018(26)00196-7","DOIUrl":"10.1016/S2352-3018(26)00196-7","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e687"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148563375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Turkish Government crackdown on HIV and LGBTQ+ groups. 土耳其政府镇压艾滋病和LGBTQ+群体。
IF 14.6 1区 医学
Lancet Hiv Pub Date : 2026-10-01 Epub Date: 2026-09-18 DOI: 10.1016/S2352-3018(26)00232-8
The Lancet Hiv
{"title":"Turkish Government crackdown on HIV and LGBTQ+ groups.","authors":"The Lancet Hiv","doi":"10.1016/S2352-3018(26)00232-8","DOIUrl":"10.1016/S2352-3018(26)00232-8","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e679"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149002639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ebola virus disease outbreaks and HIV control 埃博拉病毒病爆发和艾滋病毒控制
IF 16.1 1区 医学
Lancet Hiv Pub Date : 2026-09-30 DOI: 10.1016/s2352-3018(26)00225-0
Marguerite Massinga Loembe, Edlom P Tchadie, Selidji T Agnandji
{"title":"Ebola virus disease outbreaks and HIV control","authors":"Marguerite Massinga Loembe, Edlom P Tchadie, Selidji T Agnandji","doi":"10.1016/s2352-3018(26)00225-0","DOIUrl":"https://doi.org/10.1016/s2352-3018(26)00225-0","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"225 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet HIV 2026; 13: e557–68 《柳叶刀HIV 2026》修正;13: e557 - 68
IF 16.1 1区 医学
Lancet Hiv Pub Date : 2026-09-30 DOI: 10.1016/s2352-3018(26)00235-3
{"title":"Correction to Lancet HIV 2026; 13: e557–68","authors":"","doi":"10.1016/s2352-3018(26)00235-3","DOIUrl":"https://doi.org/10.1016/s2352-3018(26)00235-3","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"41 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet HIV 2026; 13: e440–51 《柳叶刀HIV 2026》修正;13: e440-51
IF 16.1 1区 医学
Lancet Hiv Pub Date : 2026-09-30 DOI: 10.1016/s2352-3018(26)00234-1
{"title":"Correction to Lancet HIV 2026; 13: e440–51","authors":"","doi":"10.1016/s2352-3018(26)00234-1","DOIUrl":"https://doi.org/10.1016/s2352-3018(26)00234-1","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"3 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书